Australian Interventional Pharmacotherapy and Psychedelic Assisted Psychotherapy Research Registry (AIPPAP-RR)
The project has been designed for the collection of outcome and safety data on the use of novel interventional pharmacotherapy approaches. The AIPPAP Research Registry is designed to capture real-world clinical data on the use of ketamine, MDMA, and psilocybin.
Research themes
Project status
Content navigation
About
Welcome to the Psychedelic assisted Psychotherapy Research Registry information site.
- A project developed and led by researchers at The Australian National University (ANU).
- Designed for the collection of outcome and safety data on the use of novel interventional pharmacotherapy approaches, including ketamine treatment and psychedelic-assisted psychotherapy (PAP) for mental health disorders, such as depression, post-traumatic stress disorder (PTSD) and obsessive–compulsive disorder (OCD).
The Registry is funded by Mind Medicine Australia.
Acknowledgement of Country
The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.
Members
Principal investigator
Director, ANU School of Medicine and Psychology
Senior Staff Specialist, Canberra Health Services
(EA: Cheryl Morse E: cheryl.morse@anu.edu.au)
Co-investigator
Research Officer (P Fitzgerald Research Group)
More information